BR112014004782A2 - formulações adjuvantes de antígenos de staphylococcus aureus - Google Patents

formulações adjuvantes de antígenos de staphylococcus aureus

Info

Publication number
BR112014004782A2
BR112014004782A2 BR112014004782A BR112014004782A BR112014004782A2 BR 112014004782 A2 BR112014004782 A2 BR 112014004782A2 BR 112014004782 A BR112014004782 A BR 112014004782A BR 112014004782 A BR112014004782 A BR 112014004782A BR 112014004782 A2 BR112014004782 A2 BR 112014004782A2
Authority
BR
Brazil
Prior art keywords
staphylococcus aureus
adjuvant formulations
aureus antigens
antigens
adjuvant
Prior art date
Application number
BR112014004782A
Other languages
English (en)
Portuguese (pt)
Inventor
Baudner Barbara
Bagnoli Fabio
Bufali Simone
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112014004782A2 publication Critical patent/BR112014004782A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
BR112014004782A 2011-09-01 2012-08-31 formulações adjuvantes de antígenos de staphylococcus aureus BR112014004782A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161530162P 2011-09-01 2011-09-01
US201261607999P 2012-03-07 2012-03-07
PCT/EP2012/067032 WO2013030378A1 (en) 2011-09-01 2012-08-31 Adjuvanted formulations of staphylococcus aureus antigens

Publications (1)

Publication Number Publication Date
BR112014004782A2 true BR112014004782A2 (pt) 2017-03-21

Family

ID=46763095

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014004782A BR112014004782A2 (pt) 2011-09-01 2012-08-31 formulações adjuvantes de antígenos de staphylococcus aureus

Country Status (14)

Country Link
US (1) US20140363461A1 (enExample)
EP (1) EP2763695A1 (enExample)
JP (1) JP2014525429A (enExample)
KR (1) KR20140066212A (enExample)
CN (1) CN104093418A (enExample)
AU (1) AU2012300765A1 (enExample)
BR (1) BR112014004782A2 (enExample)
CA (1) CA2847204A1 (enExample)
IL (1) IL231104A0 (enExample)
IN (1) IN2014CN02152A (enExample)
MX (1) MX2014002363A (enExample)
RU (1) RU2014112343A (enExample)
SG (1) SG11201400210RA (enExample)
WO (1) WO2013030378A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2523732T5 (es) * 2009-04-03 2023-10-23 Momenta Pharmaceuticals Inc Control de composiciones de copolímeros
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
CN105999275A (zh) 2010-09-01 2016-10-12 诺华有限公司 免疫增强剂吸附不溶性金属离子
AU2012214677B2 (en) 2011-02-08 2016-11-10 Abvacc, Inc. Immunogenic composition comprising alpha-hemolysin oligopeptides
US20140112950A1 (en) 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
KR20140066212A (ko) * 2011-09-01 2014-05-30 노파르티스 아게 스타필로코쿠스 아우레우스 항원의 보조제 첨가된 조제물
HRP20161354T1 (hr) * 2012-03-07 2016-12-02 Glaxosmithkline Biologicals Sa Argininske soli agonista tlr7
US9375471B2 (en) 2012-03-08 2016-06-28 Glaxosmithkline Biologicals Sa Adjuvanted formulations of booster vaccines
CN104619336A (zh) * 2012-08-31 2015-05-13 诺华股份有限公司 用于针对金黄色葡萄球菌的免疫的稳定化的蛋白质
US20150191513A1 (en) * 2012-08-31 2015-07-09 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
EP2890387A1 (en) * 2012-08-31 2015-07-08 Novartis AG Stabilised proteins for immunising against staphylococcus aureus
BE1022359B1 (fr) * 2014-03-17 2016-03-25 Glaxosmithkline Biologicals Sa Immunisation contre des infections staphylococciques des os et des articulations
EP3122378B1 (en) 2014-03-26 2019-12-11 GlaxoSmithKline Biologicals S.A. Mutant staphylococcal antigens
WO2015144691A1 (en) * 2014-03-26 2015-10-01 Glaxosmithkline Biologicals Sa Compositions for immunising against staphylococcus aureus
CN105646681B (zh) * 2016-01-21 2021-07-16 浙江海隆生物科技有限公司 一种奶牛金黄色葡萄球菌α-溶血素亚单位疫苗的制备方法及应用
IL263616B2 (en) 2016-07-07 2025-01-01 Univ Leland Stanford Junior Antibody-adjuvant conjugates
AR111760A1 (es) * 2017-05-19 2019-08-14 Novartis Ag Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0114787B1 (de) 1983-01-25 1991-09-25 Ciba-Geigy Ag Neue Peptidderivate
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ES2162139T5 (es) 1993-03-23 2008-05-16 Smithkline Beecham Biologicals S.A. Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado.
US20060188515A1 (en) 2003-07-24 2006-08-24 Anderson Annaliesa S Polypeptides for inducing a protective immune response against staphylococcus aureus
NZ544542A (en) 2003-07-24 2009-01-31 Merck & Co Inc Polypeptides for inducing a protective immune response against staphylococcus aureus
CA2555342A1 (en) 2004-02-18 2005-09-01 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus aureus
TWI382019B (zh) 2005-08-19 2013-01-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
TW200801003A (en) 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
JPWO2007034817A1 (ja) 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規アデニン化合物
TW200745114A (en) 2005-09-22 2007-12-16 Astrazeneca Ab Novel compounds
EP1939201A4 (en) 2005-09-22 2010-06-16 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
EP1939198A4 (en) 2005-09-22 2012-02-15 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
WO2007034916A1 (ja) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
AU2007216247A1 (en) 2006-02-17 2007-08-23 Pfizer Limited 3 -deazapurine derivatives as TLR7 modulators
AU2007259415B2 (en) 2006-06-12 2013-09-26 Glaxosmithkline Biologicals Sa Use of alpha-toxin for treating and preventing Staphylococcus infections
US8138172B2 (en) 2006-07-05 2012-03-20 Astrazeneca Ab 8-oxoadenine derivatives acting as modulators of TLR7
US8338593B2 (en) 2006-07-07 2012-12-25 Gilead Sciences, Inc. Modulators of toll-like receptor 7
WO2008152447A2 (en) 2006-10-30 2008-12-18 The University Of Western Ontario Staphylococcus aureus specific anti-infectives
TW200843779A (en) 2007-02-19 2008-11-16 Smithkline Beecham Corp Compounds
AR065784A1 (es) 2007-03-20 2009-07-01 Dainippon Sumitomo Pharma Co Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
JP5400763B2 (ja) 2007-05-08 2014-01-29 アストラゼネカ・アクチエボラーグ 免疫調節特性を有するイミダゾキノリン類
ES2359123T3 (es) 2007-08-03 2011-05-18 Pfizer Limited Imidazopiridinonas.
CA2697538C (en) 2007-08-31 2019-02-12 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
PE20091236A1 (es) 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
PL2268618T3 (pl) 2008-03-03 2015-11-30 Novartis Ag Związki i kompozycje jako modulatory aktywności receptorów TLR
CN103396415B (zh) 2008-03-24 2016-08-10 4Sc股份有限公司 新的取代的咪唑并喹啉化合物
WO2010014913A1 (en) 2008-08-01 2010-02-04 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use
NZ593110A (en) 2008-12-09 2013-06-28 Gilead Sciences Inc pteridinone derivatives as MODULATORS OF TOLL-LIKE RECEPTORS
CA2758490C (en) * 2009-04-14 2023-05-02 Novartis Ag Compositions for immunising against staphylococcus aureus
SI2445522T1 (sl) * 2009-06-22 2017-10-30 Wyeth Llc Imunogeni sestavki antigenov Staphylococcusa aureusa
AU2010272505B2 (en) 2009-07-16 2015-09-17 Glaxosmithkline Biologicals S.A. Treatment of infections
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
JO3257B1 (ar) * 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
ES2443952T3 (es) * 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
JP5848748B2 (ja) 2010-03-23 2016-01-27 アイアールエム・リミテッド・ライアビリティ・カンパニーＩｒｍ，Ｌｌｃ 感染症、炎症、呼吸器疾患などの処置に使用するｔｌｒ２アゴニストとしての化合物（システインベースのリポペプチド）および組成物
CN105999275A (zh) 2010-09-01 2016-10-12 诺华有限公司 免疫增强剂吸附不溶性金属离子
US20140112950A1 (en) * 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
KR20140066212A (ko) * 2011-09-01 2014-05-30 노파르티스 아게 스타필로코쿠스 아우레우스 항원의 보조제 첨가된 조제물
JP2015510872A (ja) * 2012-03-07 2015-04-13 ノバルティス アーゲー Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤
US20150125486A1 (en) * 2012-03-08 2015-05-07 Novartis Ag Adjuvanted formulations of pediatric antigens
US9375471B2 (en) * 2012-03-08 2016-06-28 Glaxosmithkline Biologicals Sa Adjuvanted formulations of booster vaccines
US20150191513A1 (en) * 2012-08-31 2015-07-09 Novartis Ag Stabilised proteins for immunising against staphylococcus aureus
CN104619336A (zh) * 2012-08-31 2015-05-13 诺华股份有限公司 用于针对金黄色葡萄球菌的免疫的稳定化的蛋白质
EP2890387A1 (en) * 2012-08-31 2015-07-08 Novartis AG Stabilised proteins for immunising against staphylococcus aureus
JP2015528456A (ja) * 2012-08-31 2015-09-28 ノバルティス アーゲー Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対する免疫化のための安定化されたタンパク質
RU2015106930A (ru) * 2012-09-06 2016-10-20 Новартис Аг Комбинированные вакцины с менингококком серогруппы в и к/д/с
GB201219420D0 (en) * 2012-10-29 2012-12-12 Novartis Ag Staphyloccal immunogens
TR201807340T4 (tr) * 2013-02-01 2018-06-21 Glaxosmithkline Biologicals Sa Çan benzeri reseptör agonistleri içeren immünolojik kompozisyonların intradermal yoldan verilmesi.
BE1022359B1 (fr) * 2014-03-17 2016-03-25 Glaxosmithkline Biologicals Sa Immunisation contre des infections staphylococciques des os et des articulations
WO2015144691A1 (en) * 2014-03-26 2015-10-01 Glaxosmithkline Biologicals Sa Compositions for immunising against staphylococcus aureus
EP3122378B1 (en) * 2014-03-26 2019-12-11 GlaxoSmithKline Biologicals S.A. Mutant staphylococcal antigens

Also Published As

Publication number Publication date
MX2014002363A (es) 2014-04-14
KR20140066212A (ko) 2014-05-30
US20140363461A1 (en) 2014-12-11
AU2012300765A1 (en) 2014-03-13
CA2847204A1 (en) 2013-03-07
CN104093418A (zh) 2014-10-08
EP2763695A1 (en) 2014-08-13
SG11201400210RA (en) 2014-03-28
JP2014525429A (ja) 2014-09-29
IL231104A0 (en) 2014-04-30
RU2014112343A (ru) 2015-10-10
WO2013030378A1 (en) 2013-03-07
IN2014CN02152A (enExample) 2015-09-04

Similar Documents

Publication Publication Date Title
BR112014004782A2 (pt) formulações adjuvantes de antígenos de staphylococcus aureus
BR112013016153A2 (pt) composições imunogênicas estáveis de antígenos de staphylococcus aureus
EP2747556A4 (en) pyrethroid formulations
DK3091029T5 (da) Anti-IL13-antistofformuleringer
CO6801637A2 (es) Formulaciones de anticuerpos
FR2970871B1 (fr) Mouche-bebe
DK3117837T3 (da) Antistofformuleringer
BR112012030950A2 (pt) formulações de vacina
EP2725900A4 (en) ANTIMICROBIAL COMPOSITION
CO6950492A2 (es) Composiciones plaguicidas estables
IL217084A0 (en) Immunogenic compositions of staphylococcus aureus antigens
HRP20160887T1 (hr) Formulacije testosterona
CO6900117A2 (es) Formulaciones peptídicas de liberación controlada
BR112014004779A2 (pt) formulações de derivados de decitabina
CO6870048A2 (es) Formulación herbicida mejorada
HRP20171889T1 (hr) Formulacije kombinacije darunavira
CO7020931A2 (es) Composiciones herbicidas sólidas mejoradas con adyuvante incorporado
EP2755680A4 (en) PARTICULATE VACCINE FORMULATIONS
SMT201600380B (it) Formulazioni di darunavir
IL230038B (en) Herbicidal composition
CO6791617A2 (es) Combinaciones de compuestos activos
EP2931042A4 (en) ANTHRACYCLINFORMULIERUNGEN
DK3251507T3 (da) Forbedrede insekticidformuleringer
CO6821942A2 (es) Combinaciones de compuestos activos
EP2593134A4 (en) PROTECTION BASED ON THE STAPHYLOCOCCUS AUREUS PROTEIN SA2412

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]